NVAX
Novavax, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
2.85
PEG
0.01
P/B
-10.11
P/S
1.16
EV/EBITDA
2.65
DCF Value
$-72.94
FCF Yield
-19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.3%
Operating Margin
41.3%
Net Margin
39.2%
ROE
-546.2%
ROA
37.4%
ROIC
64.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $147.1M | $17.5M | $0.11 |
| FY 2025 | $1.12B | $440.3M | $2.54 |
| Q3 2025 | $70.4M | $-202.4M | $-1.25 |
| Q2 2025 | $239.2M | $106.5M | $0.60 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.65
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.